<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>医学新闻</title><description>来自 News-Medical.Net - 来自世界各地的最新医学新闻和研究</description><link/>https://www.news-medical.net/<language> en-GB</language><item><title>急性髓性白血病的新组合和靶向治疗即将出现</title><description>随着迈阿密大学米勒医学院西尔维斯特综合癌症中心和其他学术癌症中心的研究发现，针对这种侵袭性血癌提出了新的、更有效的疗法，急性髓系白血病 (AML) 的治疗前景正在迅速发展。</description><link/> https://www.news-medical.net/news/20231211/New-combinations-and-targeted-therapies-for-acute-myeloid-leukemia-on-the-horizo​​n.aspx<comments> https://www.news-medical.net/news/20231211/New-combinations-and-targeted-therapies-for-acute-myeloid-leukemia-on-the-horizo​​n.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=fe51be02-cb19-4c58-919b-f639d5c904bf</guid><pubDate> Mon, 11 Dec 2023 15:33:05 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2017/11/Blood_picture_of_acute_myeloid_leukemia_(AML)%2c_analyze_by_microscope-Jarun_Ontakrai_8864dd9cfb3b4dff9a913aede7a7c915-620x480.jpg" width="620"><media:description><![CDATA[New combinations and targeted therapies for acute myeloid leukemia on the horizon]]></media:description></media:content></item><item><title>研究发现 CAR-T 细胞疗法对于淋巴瘤缓解患者仍然可行</title><description>迈阿密大学米勒医学院西尔维斯特综合癌症中心的研究人员领导的一项研究表明，对于在细胞疗法开始之前病情已得到缓解的淋巴瘤患者来说，CAR-T 免疫疗法仍然是一个可行的选择。</description><link/> https://www.news-medical.net/news/20231211/CAR-T-cell-therapy-remains-viable-for-病人-in-lymphoma-remission-study-finds.aspx<comments> https://www.news-medical.net/news/20231211/CAR-T-cell-therapy-remains-viable-for-病人-in-lymphoma-remission-study-finds.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=70090ab5-e057-401f-b888-5cb526341332</guid><pubDate> Mon, 11 Dec 2023 15:28:07 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2017/6/Anatomical_structure_of_biological_animal_cell_with_organelles-eranicle_1d73b50575dc4546875a4a2fc7d429a6-620x480.jpg" width="620"><media:description><![CDATA[CAR-T cell therapy remains viable for patients in lymphoma remission, study finds]]></media:description></media:content></item><item><title>正念可能是减轻阿片类药物使用障碍女性复发的关键</title><description>以正念为导向的恢复增强（更多）-；一种行为干预，整合了正念训练、情绪调节策略和享受自然奖励——；罗格斯大学的一项研究发现，这可能是减少接受药物辅助阿片类药物使用障碍治疗的女性复发的关键。</description><link/> https://www.news-medical.net/news/20231211/Mindativity-could-hold-the-key-to-mitigating-relapse-in-women-with-opioid-use-disorder.aspx<comments> https://www.news-medical.net/news/20231211/Mindativity-could-hold-the-key-to-mitigating-relapse-in-women-with-opioid-use-disorder.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=f315a47f-c2e4-4af7-8074-485c3d9880a9</guid><pubDate> Mon, 11 Dec 2023 15:24:19 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2017/6/Closeup_of_woman%27s_hands_meditating_indoors-Luna_Vandoorne_2f70c06d04f041628deee807b0c71b7e-620x480.jpg" width="620"><media:description><![CDATA[Mindfulness could hold the key to mitigating relapse in women with opioid use disorder]]></media:description></media:content></item><item><title>新药物组合显示出针对 RAS 突变多发性骨髓瘤的前景</title><description>一项针对小鼠的新研究表明，药物和蛋白质片段的结合可以防止血癌细胞的生长。</description><link/> https://www.news-medical.net/news/20231211/New-drug-combo-shows-promise-in-targeting-RAS-mutant-multiple-myeloma.aspx<comments> https://www.news-medical.net/news/20231211/New-drug-combo-shows-promise-in-targeting-RAS-mutant-multiple-myeloma.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=6485eec2-2440-4915-ac69-04f1d4d44865</guid><pubDate> Mon, 11 Dec 2023 15:20:20 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2014/7/174318220-620x480.jpg" width="620"><media:description><![CDATA[New drug combo shows promise in targeting RAS-mutant multiple myeloma]]></media:description></media:content></item><item><title>研究可为协同治疗组合更好地治疗 SF3B1 突变型 MDS 铺平道路</title><description>迈阿密大学米勒医学院西尔维斯特综合癌症中心和合作组织的研究人员进行的一项新研究深入了解了骨髓增生异常综合征（MDS）和其他骨髓肿瘤患者中常见的基因突变的潜在机制。</description><link/> https://www.news-medical.net/news/20231211/Study-could-pave-the-way-for-synergistic-therapeutic-combinations-to-better-treat-SF3B1-mutant-MDS.aspx<comments> https://www.news-medical.net/news/20231211/Study-could-pave-the-way-for-synergistic-therapeutic-combinations-to-better-treat-SF3B1-mutant-MDS.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=1c64cb00-8128-4bac-97fa-a9c8e9f7e604</guid><pubDate> Mon, 11 Dec 2023 15:16:28 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2014/7/cancer_cell-620x480.jpg" width="620"><media:description><![CDATA[Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS]]></media:description></media:content></item><item><title> MD 安德森研究人员报告了针对白血病的新型 Menin 靶向疗法的早期成功</title><description>由德克萨斯大学 MD 安德森癌症中心的研究人员领导的两项临床试验表明，针对 menin 的新疗法用于治疗具有特定基因改变的复发性或难治性急性白血病的早期积极结果。</description><link/> https://www.news-medical.net/news/20231211/MD-Anderson-researchers-report-early-success-of-novel-menin-targeted-therapies-in-leukemia.aspx<comments> https://www.news-medical.net/news/20231211/MD-Anderson-researchers-report-early-success-of-novel-menin-targeted-therapies-in-leukemia.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=e99fc922-58b0-4eb4-88a6-321cc1fde05b</guid><pubDate> Mon, 11 Dec 2023 15:04:09 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2014/6/red_blood_cells-620x480.jpg" width="620"><media:description><![CDATA[MD Anderson researchers report early success of novel menin-targeted therapies in leukemia]]></media:description></media:content></item><item><title>靶向治疗可减少疾病负担标志物，改善非晚期系统肥大细胞增多症患者的症状</title><description>根据德克萨斯大学 MD 安德森癌症中心研究人员报告的 II 期 SUMMIT 试验结果，靶向治疗 bezuclastinib 是安全的，可以快速降低疾病负担标志物，同时还能改善患有一种称为非高级系统肥大细胞增多症的罕见血液疾病的患者的症状。</description><link/> https://www.news-medical.net/news/20231211/Targeted-therapy-reduces-markers-of-disease-burden-improves-symptoms-for-病人-with-nonadvanced-system-mastocytosis.aspx<comments> https://www.news-medical.net/news/20231211/Targeted-therapy-reduces-markers-of-disease-burden-improves-symptoms-for-病人-with-nonadvanced-system-mastocytosis.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=56232a96-f127-46f3-ac33-8c8eeb50867b</guid><pubDate> Mon, 11 Dec 2023 15:02:25 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2014/7/92036744-620x480.jpg" width="620"><media:description><![CDATA[Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis]]></media:description></media:content></item><item><title>新药物组合使骨髓纤维化患者缩小肿大脾脏的效果加倍</title><description>对于患有中度或高危骨髓纤维化的成人患者，将 JAK 抑制剂鲁索替尼与 BCL-xL 抑制剂 navitoclax 联合使用，在减少脾脏肿大（临床改善的主要指标）方面的效果是标准护理鲁索替尼单药疗法的两倍，中度或高危骨髓纤维化是一种罕见的骨髓纤维化。根据德克萨斯大学 MD 安德森癌症中心研究人员报告的 III 期 TRANSFORM-1 试验结果，骨髓癌。</description><link/> https://www.news-medical.net/news/20231211/New-drug-combination-doubles-effectness-in-shrinking-enlarged-spleens-in-myelofibrosis- Patients.aspx<comments> https://www.news-medical.net/news/20231211/New-drug-combination-doubles-effectness-in-shrinking-enlarged-spleens-in-myelofibrosis- Patients.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=cd08f87e-2643-4c7a-a1f5-4f0ad2177af3</guid><pubDate> Mon, 11 Dec 2023 14:55:44 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2017/4/Test_tubes_filled_with_blood_in_laboratory-Africa_Studio_90df34ad51cd439690eb2cabb696156a-620x480.jpg" width="620"><media:description><![CDATA[New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients]]></media:description></media:content></item><item><title>达沙替尼和 blinatumomab 的组合为老年 Ph+ ALL 患者提供了有效的治疗</title><description>费城染色体阳性 (Ph+) 急性淋巴细胞白血病 (ALL) 老年患者不适合强化化疗标准治疗，但采用达沙替尼和博纳吐莫单抗替代方案后，中位总生存期 (OS) 为 6.5 年。</description><link/> https://www.news-medical.net/news/20231211/Combination-of-dasatinib-and-blinatumomab-offers- effective-treatment-for-older-Ph2b-ALL-病人.aspx<comments> https://www.news-medical.net/news/20231211/Combination-of-dasatinib-and-blinatumomab-offers- effective-treatment-for-older-Ph2b-ALL-病人.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=8db9a5b6-7569-478c-b1c8-93cec5de1292</guid><pubDate> Mon, 11 Dec 2023 14:52:40 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2014/7/Chemo_Vials-620x480.jpg" width="620"><media:description><![CDATA[Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients]]></media:description></media:content></item><item><title>新型 CAR T 细胞疗法 AT101 的 I 期临床试验显示出有希望的早期反应</title><description>研究人员表示，AT101 是一种新型 CAR T 细胞疗法，使用独特的结合机制来靶向 CD19，其 I 期临床试验的早期结果显示，在试验中研究的较高剂量水平下，完全缓解 (CR) 率为 100%来自宾夕法尼亚大学佩雷​​尔曼医学院和宾夕法尼亚大学医学院艾布拉姆森癌症中心。</description><link/> https://www.news-medical.net/news/20231211/Phase-I-clinical-trial-of-new-CAR-T-cell-therapy-AT101-shows-promising-early-responses.aspx<comments> https://www.news-medical.net/news/20231211/Phase-I-clinical-trial-of-new-CAR-T-cell-therapy-AT101-shows-promising-early-responses.aspx#comment</comments><guid> https://www.news-medical.net/post.aspx?id=e1e3b1a4-ee1d-47ab-93a0-93ec3b34c3cf</guid><pubDate> Mon, 11 Dec 2023 14:50:47 -0500</pubDate> <media:content expression="full" height="480" type="image/jpeg" url="https://d2jx2rerrg6sh3.cloudfront.net/image-handler/picture/2017/6/%40cell%2c_cell_structure%2c_cell_anatomy_in_section_on_a_white_background.-Anton_Nalivayko_3af0fca106ac4af3887f5b4af13cbaa5-620x480.jpg" width="620"><media:description><![CDATA[Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses]]></media:description></media:content></item></channel></rss>